Clinical Trial

Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

Name: Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study — clinical trial record (NCT07257055)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.

Protocol Amendment History 1 change

critical Recruitment opened 2026-04-17

Trial Details

NCT Number	NCT07257055
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Phase 2 Study, MCL, BTKi, Rituximab, Glofitamab
Enrollment	30 participants
Start Date	2026-04-01
Primary Completion	2028-11-24 (estimated)
Study Completion	2030-11-24 (estimated)
Updated on ClinicalTrials.gov	2026-05-20